مرکز منطقه ای اطلاع رساني علوم و فناوري -

چكيده لاتين :

In the last decade, explosion in thera- I peutic options for management of type 2 diabetes mellitus (OM) have increased significantly with advances in recombinant DNA technology, molecular biology, clinical chemistry; analogs of insulin have replaced animal insulin, and may displace NPH, regular lente, ultra lente, insulinיs. Analogs such as insulin glargine, insulin lispro, insulin aspart, and insulin glulisine are becoming mainstream therapy for even type 2 OM Besides oral hypoglycemic agents i.e., sulphonyl ureas, biguanides and thiazolidinediones, newer insulin analogs and non-insulin antidiabetics are in various stages of development. Incretin analogs, amylin analogs, combined P PAR-y and a agonists, isletneogenesis gene-associated protein (IN GAP) are most prominent amongst these. This review focuses on pramlintide, an amylin analog, GLP-l agonists and exenatide, an exendin 4 analog recently approved for use in type 2 diabetes by US FDA. Newer insulin delivery methods and drugs have also been reviewed.